Could Sars-Cov2 affect MS progression?

被引：14
作者：
Di Stadio, Arianna [1 ,2 ]
Romani, Luigina [3 ]
Bernitsas, Evanthia [4 ]
机构：
[1] Univ Perugia, Otolaryngol Dept, Perugia, Italy
[2] Queen Sq UCL Neurol, Neuroinflammat Lab, London, England
[3] Univ Perugia, Dept Expt Med, Perugia, Italy
[4] Wayne State Univ, Multiple Sclerosis Ctr, Detroit, MI USA
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 46卷
关键词：
COVID-19; Sars-CoV2 Multiple sclerosis; Inflammasomes; Microglia; Long-term sequela; NLRP3;
D O I：
10.1016/j.msard.2020.102540
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A long-term neurologic sequela arising from COVID-19 infection in multiple sclerosis (MS) patients could be related both to the increase of cytokines and the activation of NLRP3 inflammasome by the Sars-CoV2. These two mechanisms may cause a worsening of MS several months after the resolution of the infection.
引用
收藏
页数：2
相关论文
共 14 条
[1]   COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination [J].
Boziki, Marina Kleopatra ;
Mentis, Alexios-Fotios A. ;
Shumilina, Maria ;
Makshakov, Gleb ;
Evdoshenko, Evgeniy ;
Grigoriadis, Nikolaos .
BRAIN SCIENCES, 2020, 10 (06)
[2]   Microglia polarization by mitochondrial metabolism modulation: A therapeutic opportunity in neurodegenerative diseases [J].
Di Stadio, Arianna ;
Angelini, Corrado .
MITOCHONDRION, 2019, 46 :334-336
[3]   Targeting the NLRP3 Inflammasome in Severe COVID-19 [J].
Freeman, Tracey L. ;
Swartz, Talia H. .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[4]   Cytokines as Mediators of Neuroinflammation in Experimental Autoimmune Encephalomyelitis [J].
Gogoleva, V. S. ;
Atretkhany, K. -S. N. ;
Drutskaya, M. S. ;
Mufazalov, I. A. ;
Kruglov, A. A. ;
Nedospasov, S. A. .
BIOCHEMISTRY-MOSCOW, 2018, 83 (09) :1089-1103
[5]   Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets [J].
Govindarajan, Vaidya ;
de Rivero Vaccari, Juan Pablo ;
Keane, Robert W. .
JOURNAL OF NEUROINFLAMMATION, 2020, 17 (01)
[6]   Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation [J].
Guarda, Greta ;
Braun, Marion ;
Staehli, Francesco ;
Tardivel, Aubry ;
Mattmann, Chantal ;
Foerster, Irmgard ;
Farlik, Matthias ;
Decker, Thomas ;
Du Pasquier, Renaud A. ;
Romero, Pedro ;
Tschopp, Juerg .
IMMUNITY, 2011, 34 (02) :213-223
[7]   Asymptomatic and Symptomatic Patients With Non-severe Coronavirus Disease (COVID-19) Have Similar Clinical Features and Virological Courses: A Retrospective Single Center Study [J].
Li, Yanli ;
Shi, Jie ;
Xia, Jianbo ;
Duan, Jie ;
Chen, Lijuan ;
Yu, Xudong ;
Lan, Weishun ;
Ma, Quanfu ;
Wu, Xufeng ;
Yuan, Yichong ;
Gong, Liyan ;
Yang, Xinghai ;
Gao, Han ;
Wu, Chunchen .
FRONTIERS IN MICROBIOLOGY, 2020, 11
[8]   Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages [J].
Merad, Miriam ;
Martin, Jerome C. .
NATURE REVIEWS IMMUNOLOGY, 2020, 20 (06) :355-362
[9]   Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis [J].
Soares, Jaine L. S. ;
Oliveira, Enedina M. L. ;
Pontillo, Alessandra .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 :26-34
[10]   An Italian programme for COVID-19 infection in multiple sclerosis [J].
Sormani, Maria Pia .
LANCET NEUROLOGY, 2020, 19 (06) :481-482
12